Arbutus Biopharma (ABUS) Reports In-Line Q1 EPS

Arbutus Biopharma (NASDAQ: ABUS) reported Q1 EPS of ($0.10), in-line with the analyst estimate of ($0.10). Revenue for the quarter came in at $1.53 million versus the consensus estimate of $4.51 million.

For earnings history and earnings-related data on Arbutus Biopharma (ABUS) click here.

You May Also Be Interested In

• FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
• Cerebras Systems (CBRS) Misses Q1 EPS, Revenues Beat
• RBC initiates GE HealthCare as it sees AI-led innovation cycle driving growth